Literature DB >> 12859615

A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?

Yvon Gauthier1, Muriel Cario Andre, Alain Taïeb.   

Abstract

Common generalized vitiligo is an acquired depigmenting disorder characterized by a chronic and progressive loss of melanocytes from the epidermis and follicular reservoir. However, the mechanism of melanocyte disappearance has never been clearly understood, and the intervention of cellular and humoral autoimmune phenomena as primary events remains unproven. In this review, is discussed the data supporting the major theories of vitiligo, namely melanocyte destruction (autoimmune, neural and impaired redox status) and melanocyte inhibition or defective adhesion. Based on recent morphologic findings in vivo supporting a chronic detachment and transepidermal loss of melanocytes in common generalized vitiligo, a new theory is suggested proposing melanocytorrhagy as the primary defect underlying melanocyte loss, integrating most of the possible triggering/precipitating/enhancing effects of other known factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859615     DOI: 10.1034/j.1600-0749.2003.00070.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  44 in total

1.  Oxidative stress-induced overexpression of miR-25: the mechanism underlying the degeneration of melanocytes in vitiligo.

Authors:  Q Shi; W Zhang; S Guo; Z Jian; S Li; K Li; R Ge; W Dai; G Wang; T Gao; C Li
Journal:  Cell Death Differ       Date:  2015-08-28       Impact factor: 15.828

2.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

Review 3.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

4.  Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo.

Authors:  Nesrine Boukhedouni; Christina Martins; Anne-Sophie Darrigade; Claire Drullion; Jérôme Rambert; Christine Barrault; Julien Garnier; Clément Jacquemin; Denis Thiolat; Fabienne Lucchese; Franck Morel; Khaled Ezzedine; Alain Taieb; François-Xavier Bernard; Julien Seneschal; Katia Boniface
Journal:  JCI Insight       Date:  2020-06-04

5.  Chemical Leukoderma Improved by Low-dose Steroid Pulse Therapy.

Authors:  Jae Yoon Jung; Kkot Bora Yeom; Hee Chul Eun
Journal:  Ann Dermatol       Date:  2010-05-19       Impact factor: 1.444

6.  [Vitiligo. What is new?].

Authors:  K U Schallreuter; M M A E L Salem
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

7.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

8.  CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population.

Authors:  Farha Deeba; Rabbani Syed; Jariya Quareen; M A Waheed; Kaiser Jamil; Hanmanth Rao
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

9.  Tumor necrosis factor-α -308G/A polymorphism is associated with active vitiligo vulgaris in a northeastern Mexican population.

Authors:  Mauricio Salinas-Santander; Daniel Díaz-García; Augusto Rojas-Martínez; Cristina Cantú-Salinas; Celia Sánchez-Domínguez; Miguel Reyes-López; Ricardo M Cerda-Flores; Jorge Ocampo-Candiani; Rocío Ortiz-López
Journal:  Exp Ther Med       Date:  2012-03-09       Impact factor: 2.447

10.  Bowman lecture on the role of inflammation in degenerative disease of the eye.

Authors:  J V Forrester
Journal:  Eye (Lond)       Date:  2013-01-04       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.